Table 2 Cost-effectiveness ratios for intermediate degrees of vaccine efficacy in preventing cases of NBPD in 5 European countries.
From: Policymaking based on CERs: changes in costs are not the same as changes in benefits
Assumed preventive Power against NBPD | Belgium | France | Scotland | Spain | Sweden |
|---|---|---|---|---|---|
0% effectiveness against NBPD | 25907 | 19182 | 14892 | 10511 | 32675 |
Step 1 (10% increase) | 13678 | 15801 | 6858 | 4383 | 10158 |
Step 2 (20% increase) | 8313 | 13085 | 4167 | 2126 | 4217 |
Step 3 (30% increase) | 5300 | 10857 | 2820 | 954 | 1473 |
Step 4 (40% increase) | 3370 | 8995 | 2010 | 235 | Cost saving |
Step 5 (50% increase) | 2028 | 7415 | 1470 | Cost saving | Cost saving |
Step 6 (60% increase) | 1041 | 6058 | 1084 | Cost saving | Cost saving |
Step 7 (70% increase) | 285 | 4881 | 795 | Cost saving | Cost saving |
Step 8 (80% increase) | Cost saving | 3849 | 570 | Cost saving | Cost saving |
Step 9 (90% increase) | Cost saving | 2938 | 390 | Cost saving | Cost saving |
Step 10 (same effectiveness against NBPD as against BPD) | Cost saving | 2127 | 242 | Cost saving | Cost saving |